MBA MD - Immix Biopharma Chairman CoFounder
| IMMX Stock | USD 1.68 0.14 7.69% |
Insider
MBA MD is Chairman CoFounder of Immix Biopharma
| Age | 49 |
| Address | 11400 West Olympic Boulevard, Los Angeles, CA, United States, 90064 |
| Phone | 310 651 8041 |
| Web | https://www.immixbio.com |
Immix Biopharma Management Efficiency
The company has return on total asset (ROA) of (0.5685) % which means that it has lost $0.5685 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0381) %, meaning that it created substantial loss on money invested by shareholders. Immix Biopharma's management efficiency ratios could be used to measure how well Immix Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.81 in 2024. Return On Capital Employed is likely to rise to -0.95 in 2024. At this time, Immix Biopharma's Net Tangible Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 144.3 K in 2024, whereas Total Assets are likely to drop slightly above 12 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Jay Cross | Sonnet Biotherapeutics Holdings | 53 | |
| Joseph Ferra | Elevation Oncology | 49 | |
| Susan Dexter | Sonnet Biotherapeutics Holdings | 69 | |
| Launa Aspeslet | Hepion Pharmaceuticals | N/A | |
| Valerie MD | Elevation Oncology | 46 | |
| LaBella MS | ZyVersa Therapeutics | 66 | |
| MD FACP | Sonnet Biotherapeutics Holdings | 66 | |
| CPA CTP | Cns Pharmaceuticals | 44 | |
| Stephen MD | Hepion Pharmaceuticals | N/A | |
| Ibrahim MD | Enveric Biosciences | 55 | |
| Peter Facchini | Enveric Biosciences | 60 | |
| MBA IV | Enveric Biosciences | 68 | |
| Avani Kanubaddi | Enveric Biosciences | 51 | |
| BSc BSc | Hepion Pharmaceuticals | 66 | |
| Donald Picker | Cns Pharmaceuticals | 78 | |
| Sharen Pyatetskaya | Hepion Pharmaceuticals | ||
| RPh PharmD | Elevation Oncology | 40 | |
| Ryan Bloomer | Elevation Oncology | N/A | |
| Joseph Tucker | Enveric Biosciences | 55 | |
| Brian Sullivan | Elevation Oncology | N/A | |
| John Cini | Sonnet Biotherapeutics Holdings | 71 | |
Management Performance
| Return On Equity | -1.04 | ||||
| Return On Asset | -0.57 |
Immix Biopharma Leadership Team
Elected by the shareholders, the Immix Biopharma's board of directors comprises two types of representatives: Immix Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Immix. The board's role is to monitor Immix Biopharma's management team and ensure that shareholders' interests are well served. Immix Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Immix Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| JD MBA, CoFounder | ||
| David Marks, Chief Therapy | ||
| Gabriel BA, CFO Director | ||
| Gerhard Bauer, Head Manufacturing | ||
| MD FFPM, Chief Development | ||
| Nandan BS, Manufacturing Chemistry | ||
| MBA MD, Chairman CoFounder | ||
| Ben JD, Executive Counsel | ||
| DSc MSE, Scientific CoFounder |
Immix Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Immix Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.04 | ||||
| Return On Asset | -0.57 | ||||
| Current Valuation | 31.46 M | ||||
| Shares Outstanding | 27.51 M | ||||
| Shares Owned By Insiders | 40.09 % | ||||
| Shares Owned By Institutions | 17.64 % | ||||
| Number Of Shares Shorted | 434.94 K | ||||
| Price To Book | 2.85 X | ||||
| EBITDA | (16.14 M) | ||||
| Net Income | (15.6 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Immix Stock Analysis
When running Immix Biopharma's price analysis, check to measure Immix Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immix Biopharma is operating at the current time. Most of Immix Biopharma's value examination focuses on studying past and present price action to predict the probability of Immix Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immix Biopharma's price. Additionally, you may evaluate how the addition of Immix Biopharma to your portfolios can decrease your overall portfolio volatility.